首页> 外文OA文献 >A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

【2h】

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

机译：一线厄洛替尼前瞻性II期开放标签研究（JO22903）在日本患有表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌（NSCLC）患者中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Goto Koichi; Nishio Makoto; Yamamoto Noboru; Chikamori Kenichi; Hida Toyoaki; Maemondo Makoto; Katakami Nobuyuki; Kozuki Toshiyuki; Yoshioka Hiroshige; Seto Takashi; Fukuyama Tamaki; Tamura Tomohide;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC) [J] . GotoK., NishioM., YamamotoN., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2013,第1期

机译：一线厄洛替尼的前瞻性II期开放标签研究（JO22903）在日本患有表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌（NSCLC）患者中
2. Quality of life (QoL) analyses from optimal (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) [J] . ChenG., FengJ., ZhouC., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第6期

机译：生活质量（QoL）来自最优（CTONG-0802）的分析，该研究为晚期EGFR突变阳性非小细胞肺癌（NSCLC）患者一线厄洛替尼与化疗一线治疗的III期随机，开放标签研究
3. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study [J] . Wu Y. -L., Zhou C., Liam C. -K., Annals of oncology: official journal of the European Society for Medical Oncology . 2015,第9期

机译：一线埃洛替尼与吉西他滨/顺铂治疗晚期EGFR突变阳性的非小细胞肺癌患者：来自III期，随机，开放标签，ENSURE研究的分析
4. Effect of preoperative cancer treatment on epidermal growth factor receptor (EGFR) receptor expression level in ABY-029 guided sarcoma surgery [C] . Xiaochun Xu, Kimberley S Samkoe, Eric R. Henderson Society of Photo-Optical Instrumentation Engineers;Conference on Molecular-Guided Surgery: Molecules, Devices, and Applications . 2020

机译：术前癌症治疗对ABY-029导向肉瘤手术中表皮生长因子受体（EGFR）受体表达水平的影响
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Final overall survival in JO22903 a phase II open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer [O] . Noboru Yamamoto, Koichi Goto, Makoto Nishio, -1

机译：JO22903的最终总体生存期这是一项针对日本EGFR突变阳性非小细胞肺癌患者的一线埃罗替尼的II期开放标签研究
7. Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer [O] . Noboru Yamamoto, Koichi Goto, Makoto Nishio, 2016

机译：JO22903的最终总体生存期，这是一项针对日本EGFR突变阳性非小细胞肺癌患者的一线埃罗替尼的II期开放标签研究

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

著录项

引文网络

相似文献

相关主题

期刊订阅